Literature DB >> 28054285

Drug Interactions in Neurocritical Care.

Brian Spoelhof1, Salia Farrokh2, Lucia Rivera-Lara3.   

Abstract

Drug-drug interactions (DDIs) are common and avoidable complications that are associated with poor patient outcomes. Neurocritical care patients may be at particular risk for DDIs due to alterations in pharmacokinetic profiles and exposure to medications with a high DDI risk. This review describes the principles of DDI pharmacology, common and severe DDIs in Neurocritical care, and recommendations to minimize adverse outcomes. A review of published literature was performed using PubMed by searching for 'Drug Interaction' and several high DDI risk and common neurocritical care medications. Key medication classes included anticoagulants, antimicrobials, antiepileptics, antihypertensives, sedatives, and selective serotonin reuptake inhibitors. Additional literature was also reviewed to determine the risk in neurocritical care and potential therapeutic alternatives. Clinicians should be aware of interactions in this setting, the long-term complications, and therapeutic alternatives.

Entities:  

Keywords:  Adverse drug reactions; Antiepileptics; Calcium channel blockers; Drug interactions; Drug metabolism; Neurocritical care

Mesh:

Substances:

Year:  2017        PMID: 28054285     DOI: 10.1007/s12028-016-0369-0

Source DB:  PubMed          Journal:  Neurocrit Care        ISSN: 1541-6933            Impact factor:   3.210


  75 in total

1.  Intracerebral hemorrhage after liver transplantation.

Authors:  W L Wang; Z F Yang; C M Lo; C L Liu; S T Fan
Journal:  Liver Transpl       Date:  2000-05       Impact factor: 5.799

2.  MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine.

Authors:  A van Helvoort; A J Smith; H Sprong; I Fritzsche; A H Schinkel; P Borst; G van Meer
Journal:  Cell       Date:  1996-11-01       Impact factor: 41.582

3.  Potentially serious drug interactions secondary to high-dose diltiazem used in the treatment of pulmonary hypertension.

Authors:  W R Clarke; J R Horn; I Kawabori; S Gurtel
Journal:  Pharmacotherapy       Date:  1993 Jul-Aug       Impact factor: 4.705

4.  Panipenem, a carbapenem antibiotic, enhances the glucuronidation of intravenously administered valproic acid in rats.

Authors:  N Yamamura; K Imura; H Naganuma; K Nishimura
Journal:  Drug Metab Dispos       Date:  1999-06       Impact factor: 3.922

Review 5.  Management of Serotonin Syndrome and Neuroleptic Malignant Syndrome.

Authors:  Linn E Katus; Steven J Frucht
Journal:  Curr Treat Options Neurol       Date:  2016-09       Impact factor: 3.598

6.  Statin toxicity from macrolide antibiotic coprescription: a population-based cohort study.

Authors:  Amit M Patel; Salimah Shariff; David G Bailey; David N Juurlink; Sonja Gandhi; Muhammad Mamdani; Tara Gomes; Jamie Fleet; Y Joseph Hwang; Amit X Garg
Journal:  Ann Intern Med       Date:  2013-06-18       Impact factor: 25.391

Review 7.  Pharmacology and mechanisms of action of calcium-channel blockers.

Authors:  A M Katz
Journal:  J Clin Hypertens       Date:  1986-09       Impact factor: 3.738

8.  Acute seizures in a patient receiving divalproex sodium after starting ertapenem therapy.

Authors:  Jesse L Lunde; Robert E Nelson; Harrison F Storandt
Journal:  Pharmacotherapy       Date:  2007-08       Impact factor: 4.705

9.  Dexmedetomidine preserves attention/calculation when used for cooperative and short-term intensive care unit sedation.

Authors:  Haley E Goodwin; Randeep S Gill; Peter N Murakami; Carol B Thompson; John J Lewin; Marek A Mirski
Journal:  J Crit Care       Date:  2013-10-18       Impact factor: 3.425

Review 10.  Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring.

Authors:  Shu-Feng Zhou; Charlie Changli Xue; Xue-Qing Yu; Chunguang Li; Guangji Wang
Journal:  Ther Drug Monit       Date:  2007-12       Impact factor: 3.681

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.